NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion. First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders. Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million). Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023.